Founded in 1993, The Surgical Company (TSC), headquartered in The Netherlands, has grown both organically and through mergers and acquisitions to become a Group of 9 companies. TSC’s main activities are concentrated on the development, production and distribution of specialised medical products. The group employs 370 colleagues and generates € 140 mln in annual sales.
Hemologic B.V. is a Dutch R&D company and a part of The Surgical Company (located in Amersfoort, The Netherlands). Hemologic B.V. aims to introduce a novel non-invasive cardiac diagnostic and monitoring technology, for use in the assessment of the hemodynamic function of the heart by measuring atrial and ventricular filling curves.
Drs. Luc Van Schil - CEOof The Surgical Company Group, INSEAD MBA graduate, has a background in business consulting with McKinsey, and became an entrepreneur for surgical specialties, founding the Surgical Company in 1993 which has grown in a Group holding of 7 companies with a cumulative revenue of 80 million euro in 2015. Mr. van Schil has a long experience with mergers and acquisitions, medical distribution, and development of proprietary medical products manufactured either in house or through outsourcing, which are then distributed either directly by the other surgical company group companies or through distributors.
Drs. Charles Hollenkamp MD - Managing Director Hemologic, INSEAD MBA graduate, involved in the project since 2001 as an investor, also with a background in business consulting and an entrepreneur in healthcare, real estate and hospitality markets. Graduated as Medical doctor at the University of Amsterdam. Developed a number of private medical diagnostic centers (Meditel) in The Netherlands. Also serves as the medical affairs liaison to the project.
Drs. Ewoud Welten - CFOof The Surgical Company Group since April 2020. Prior to joining TSC, Mr. Welten acted amongst others as the CFO of Biocartis, a Euronext listed MDx company, and as vice president corporate finance at the investment bank Kempen & Co, with a focus on the life sciences and healthcare sector. Mr. Welten holds a Master Degree in financial economics from the Erasmus University Rotterdam.
Principal members of the Hemologic project team
Dr. Henk Goovaerts - Biomedical and Electrical engineer consultant with a vast experience in development of haemodynamic measuring systems, involved since the inception of the company in 1993, has developed most of the electronic design and continues to contribute to the development of the associated electronics of the Hemodynamic Cardiac Profiler.
Dr. Maurits Konings -Clinical Physicist, University Medical Centre Utrecht, Project leader for the UMCU members working on the portable HCP. Invented the Field Recognition technique used in HCP and designed the mathematics and associated algorithm used for display of the filling curves.
Reviews from professionals
The ECG measures the electric activity of cardiac tissues, during which the heart aims at performing volumetric displacements of blood. However, the ECG does not register to what extent the heart has been successful in actually accomplishing these displacements. In brief:If the ECG represents what the heart is trying to do, HCP shows to what extent such has been accomplished.
Maurits Konings, PhD, University Medical Centre Utrecht, The Netherlands